0001209191-20-063343.txt : 20201214 0001209191-20-063343.hdr.sgml : 20201214 20201214192012 ACCESSION NUMBER: 0001209191-20-063343 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201210 FILED AS OF DATE: 20201214 DATE AS OF CHANGE: 20201214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rhodes Jason P CENTRAL INDEX KEY: 0001577014 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 201387764 MAIL ADDRESS: STREET 1: C/O EPIZYME, INC. STREET 2: 400 TECHNOLOGY SQUARE, 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-10 0 0001737953 Replimune Group, Inc. REPL 0001577014 Rhodes Jason P 18 COMMERCE WAY WOBURN MA 01801 1 0 0 0 Common Stock 2020-12-10 4 S 0 12691 42.68 D 2371734 I See Footnote Common Stock 2020-12-10 4 S 0 8666 43.48 D 2363068 I See Footnote Common Stock 2020-12-10 4 S 0 2653 44.35 D 2360415 I See Footnote Common Stock 2020-12-10 4 S 0 4389 42.68 D 988942 I See Footnote Common Stock 2020-12-10 4 S 0 2996 43.48 D 985946 I See Footnote Common Stock 2020-12-10 4 S 0 917 44.35 D 985029 I See Footnote Common Stock 2020-12-10 4 S 0 1099 42.68 D 28649 I See Footnote Common Stock 2020-12-10 4 S 0 750 43.48 D 27899 I See Footnote Common Stock 2020-12-10 4 S 0 230 44.35 D 27669 I See Footnote Common Stock 2020-12-11 4 S 0 19712 43.32 D 2340703 I See Footnote Common Stock 2020-12-11 4 S 0 2374 43.92 D 2338329 I See Footnote Common Stock 2020-12-11 4 S 0 6817 43.32 D 978212 I See Footnote Common Stock 2020-12-11 4 S 0 821 43.92 D 977391 I See Footnote Common Stock 2020-12-11 4 S 0 1707 43.32 D 25962 I See Footnote Common Stock 2020-12-11 4 S 0 205 43.92 D 25757 I See Footnote Common Stock 2020-12-14 4 S 0 2776 42.69 D 2335553 I See Footnote Common Stock 2020-12-14 4 S 0 21428 43.54 D 2314125 I See Footnote Common Stock 2020-12-14 4 S 0 2087 44.06 D 2312038 I See Footnote Common Stock 2020-12-14 4 S 0 961 42.69 D 976430 I See Footnote Common Stock 2020-12-14 4 S 0 7409 43.54 D 969021 I See Footnote Common Stock 2020-12-14 4 S 0 722 44.06 D 968299 I See Footnote Common Stock 2020-12-14 4 S 0 240 42.69 D 25517 I See Footnote Common Stock 2020-12-14 4 S 0 1855 43.54 D 23662 I See Footnote Common Stock 2020-12-14 4 S 0 181 44.06 D 23481 I See Footnote Shares were sold pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.15 to $43.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (8), (9), (10), (11) and (12). The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.15 to $44.11 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.15 to $44.46 inclusive. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any. The shares are held directly by AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims beneficial ownership of such securities held by AVA X LP, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.72 to $43.71 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.725 to $44.18 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.98 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.99 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.00 to $44.13 inclusive. /s/ Ommer Chohan, Attorney-in-Fact 2020-12-14